Department Clinical and Biological Sciences, Unit of Experimental Medicine and Clinical Pathology, University of Torino, Corso Raffaello 30, 10125 Torino, Italy.
Int J Mol Sci. 2019 Jun 1;20(11):2700. doi: 10.3390/ijms20112700.
Fibrogenic progression of chronic liver disease, whatever the etiology, is characterized by persistent chronic parenchymal injury, chronic activation of inflammatory response, and sustained activation of liver fibrogenesis, and of pathological wound healing response. A critical role in liver fibrogenesis is played by hepatic myofibroblasts (MFs), a heterogeneous population of α smooth-muscle actin-positive cells that originate from various precursor cells through a process of activation and transdifferentiation. In this review, we focus the attention on the role of extracellular signal-regulated kinase (ERK) signaling pathway as a critical one in modulating selected profibrogenic phenotypic responses operated by liver MFs. We will also analyze major therapeutic antifibrotic strategies developed in the last two decades in preclinical studies, some translated to clinical conditions, designed to interfere directly or indirectly with the Ras/Raf/MEK/ERK signaling pathway in activated hepatic MFs, but that also significantly increased our knowledge on the biology and pathobiology of these fascinating profibrogenic cells.
慢性肝病的纤维化进展,无论病因如何,其特征为持续的慢性实质损伤、慢性炎症反应激活和持续的肝纤维化以及病理性伤口愈合反应激活。肝肌成纤维细胞(MFs)在肝纤维化中起着关键作用,它是一群α平滑肌肌动蛋白阳性的异质性细胞,通过激活和转分化过程起源于各种前体细胞。在这篇综述中,我们将重点关注细胞外信号调节激酶(ERK)信号通路在调节肝 MF 所执行的特定促纤维化表型反应中的关键作用。我们还将分析过去二十年中在临床前研究中开发的主要抗纤维化治疗策略,其中一些已转化为临床条件,旨在直接或间接地干扰激活的肝 MF 中的 Ras/Raf/MEK/ERK 信号通路,但也极大地增加了我们对这些迷人的促纤维化细胞的生物学和病理生物学的了解。